List of Excipients in Branded Drug OPDIVO QVANTIG

OPDIVO QVANTIG Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

OPDIVO QVANTIG is Bristol Myers Squibb's subcutaneous formulation of nivolumab combined with recombinant human hyaluronidase. The product uses hyaluronidase-nvhy to enable delivery of a large-volume biologic into subcutaneous tissue, while a conventional protein-stabilizing excipient system supports nivolumab and enzyme stability. Its commercial value is tied to shorter administration time, reduced infusion-center resource use, and differentiated lifecycle management for the OPDIVO franchise.

The primary excipient opportunities are in pharmaceutical-grade polysorbate 80, trehalose, histidine buffer components, methionine, recombinant hyaluronidase technology, low-particulate packaging, and ready-to-use injectable manufacturing. Direct substitution opportunities are limited because changes to the excipient system could affect aggregation, particle formation, potency, viscosity, container compatibility, and subcutaneous tolerability.

What is OPDIVO QVANTIG and how is it administered?

OPDIVO QVANTIG contains nivolumab and hyaluronidase-nvhy in a single subcutaneous injection. The FDA approved the product on December 27, 2024, for multiple adult oncology indications involving nivolumab, including selected lung, renal, melanoma, urothelial, colorectal, esophageal, gastric, hepatocellular, head and neck, and other cancers. The exact indication and dosing schedule depend on the cancer type and whether nivolumab is used alone or with another therapy. [1]

The commercial presentation is a single-dose vial containing:

Attribute	OPDIVO QVANTIG
Active antibody	Nivolumab
Enzyme	Hyaluronidase-nvhy
Strength	600 mg nivolumab and 10,000 units hyaluronidase-nvhy per 3.5 mL
Route	Subcutaneous injection
Typical interval	Every two weeks for the labeled 600 mg/10,000-unit regimen; other nivolumab schedules depend on indication
Storage	Refrigerated at 2°C to 8°C
Dosage form	Sterile, preservative-free injectable solution
Sponsor	Bristol Myers Squibb
FDA approval	December 27, 2024

The product is supplied as a ready-to-use liquid. The label instructs healthcare professionals not to shake the vial and to protect it from freezing. [1]

What excipients are used in OPDIVO QVANTIG?

The disclosed excipient system includes histidine, histidine hydrochloride monohydrate, methionine, polysorbate 80, trehalose dihydrate, and water for injection. [1]

Excipient	Primary formulation role	Commercial relevance
Histidine	Buffering and pH control	Requires tight control of purity, bioburden, endotoxin, and trace impurities
Histidine hydrochloride monohydrate	Complements the histidine buffer system	Used to establish and maintain the target pH
Methionine	Oxidation control for the antibody and potentially the enzyme	High-value quality attribute because oxidation can affect potency and stability
Polysorbate 80	Surfactant that reduces interfacial stress and adsorption	Sensitive to oxidation, hydrolysis, peroxide burden, and lot variability
Trehalose dihydrate	Stabilizes proteins during storage and handling	Supports conformational stability and reduces aggregation risk
Water for injection	Injectable vehicle	Must meet compendial and microbiological requirements
Hyaluronidase-nvhy	Enzymatic permeation technology, rather than a conventional excipient	Enables subcutaneous dispersion of the biologic dose

Hyaluronidase is the central formulation-enabling component. It temporarily depolymerizes hyaluronan in the extracellular matrix, increasing local tissue permeability and allowing a large biologic dose to disperse under the skin. The effect is transient and supports absorption without requiring an intravenous infusion. [1,2]

How does the excipient strategy support subcutaneous delivery?

Subcutaneous delivery creates different formulation constraints from intravenous administration. The formulation must maintain protein stability in a concentrated, low-volume or moderate-volume solution while limiting injection-site discomfort, aggregation, particulate formation, and local tissue irritation.

The OPDIVO QVANTIG system addresses these requirements through four design choices.

Protein stabilization

Trehalose provides preferential hydration around the protein and helps limit conformational destabilization. Histidine maintains pH, while methionine provides an oxidation-sensitive sacrificial component. These functions are important for nivolumab, a monoclonal antibody with long-term storage requirements, and for the co-formulated hyaluronidase enzyme.

Interfacial protection

Polysorbate 80 reduces adsorption of nivolumab and hyaluronidase to vial, stopper, syringe, and air-liquid interfaces. This is particularly important during shipping, handling, dose withdrawal, and administration.

Polysorbate 80 is also a source of manufacturing and quality risk. Its degradation can generate subvisible particles, free fatty acids, and peroxide-related impurities. A supplier's control strategy must therefore address raw-material variability, oxidation, hydrolysis, and storage conditions.

Tissue permeation

Hyaluronidase-nvhy is the delivery-enabling element. It creates a temporary increase in subcutaneous permeability, allowing nivolumab to be administered outside the intravenous setting. The formulation must preserve enzymatic activity while avoiding excessive local irritation and maintaining antibody potency.

Injection-site tolerability

The formulation must balance concentration, pH, osmolality, viscosity, enzyme activity, and injection volume. Excipient changes that improve long-term stability may worsen injection force or local tolerability. This limits the practical value of simple substitution with lower-cost excipients.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not a single commodity excipient. It is supply-chain participation in a high-value sterile biologic product with stringent quality requirements.

Polysorbate 80

Pharmaceutical-grade polysorbate 80 has the clearest recurring opportunity. Suppliers can compete on:

• Low peroxide and low aldehyde content
• Consistent fatty-acid composition
• Reduced lot-to-lot variability
• Improved resistance to oxidation and hydrolysis
• Trace-metal control
• Global regulatory documentation
• Supply continuity for commercial-scale manufacturing

A supplier with a qualified grade may have a higher switching barrier than a supplier offering only a lower unit price. Changing polysorbate 80 can trigger extensive comparability work because the excipient affects particles, aggregation, oxidation, and potency.

Trehalose dihydrate

Trehalose is a relatively established biologic stabilizer, but commercial differentiation remains possible through:

• High purity
• Low endotoxin
• Low bioburden
• Controlled moisture
• Reliable crystallinity and particle-size characteristics
• Scalable pharmaceutical manufacturing
• Dual-region supply

Trehalose suppliers can target both the antibody product and other subcutaneous biologics that use concentrated protein formulations.

Histidine and methionine

Histidine, histidine hydrochloride, and methionine are lower-value materials on a per-dose basis but remain strategically important. The commercial value lies in qualified, validated supply rather than margin per kilogram.

Potential supplier differentiation includes:

• Compendial compliance
• Trace-metal control
• Low endotoxin
• Consistent assay and impurity profiles
• Supply agreements covering North America, Europe, and Asia
• Documentation supporting biologics license applications and post-approval changes

Recombinant hyaluronidase

Hyaluronidase is the highest-value formulation technology in the product. The opportunity is concentrated among companies that can produce, license, or develop recombinant human hyaluronidase platforms.

Relevant commercial models include:

1. Direct enzyme supply to biologics manufacturers.
2. Platform licensing for subcutaneous delivery.
3. Co-development agreements for new antibody-enzyme combinations.
4. Contract development and manufacturing for enzyme drug substance.
5. Device and formulation integration for high-volume injections.

The key barrier is not merely producing hyaluronidase. It is demonstrating consistent enzymatic activity, purity, stability, immunogenicity control, and compatibility with the selected antibody and container system.

What manufacturing and intellectual-property barriers affect the opportunity?

The commercial barriers are higher for hyaluronidase and the finished combination product than for standard buffer components.

Manufacturing barriers

A qualified supplier must control:

• Enzyme activity and specific activity
• Host-cell proteins and host-cell DNA
• Aggregates and fragments
• Glycosylation or other product-quality attributes
• Bioburden and endotoxin
• Sterile filtration performance
• Compatibility with the monoclonal antibody
• Hold-time and shipping stability
• Vial, stopper, and syringe interactions

The final drug product is a combination of an antibody and an enzyme. This creates more demanding analytical requirements than a conventional nivolumab formulation.

Intellectual-property barriers

The protectable elements may include:

• Antibody-hyaluronidase combinations
• Specific concentration ranges
• Buffer and stabilizer systems
• Subcutaneous administration methods
• Dosing schedules
• Indication-specific use
• Enzyme variants and formulations
• Container-closure systems
• Manufacturing and purification processes

The underlying hyaluronidase platform has been associated with commercial licensing and collaboration models in subcutaneous biologics. Suppliers and competing drug developers must assess both composition-of-matter rights and method-of-use rights before commercializing a competing formulation.

Excipient suppliers generally do not control the full product patent estate. Their leverage is more often contractual and technical: qualification status, validated manufacturing processes, change-control obligations, and the cost of replacing a supplier after regulatory approval.

How does OPDIVO QVANTIG compare with intravenous OPDIVO?

Commercial factor	Intravenous OPDIVO	OPDIVO QVANTIG
Administration	Infusion-center administration	Subcutaneous injection
Delivery technology	Standard IV biologic delivery	Nivolumab combined with hyaluronidase-nvhy
Administration time	Longer, depending on regimen and preparation	Shorter administration process
Facility dependence	Requires infusion infrastructure	Can reduce infusion-chair and IV-resource requirements
Excipient complexity	Established nivolumab IV formulation	Antibody-enzyme compatibility is required
Supply-chain requirements	Nivolumab drug substance and conventional injectable excipients	Nivolumab, recombinant hyaluronidase, excipients, and combination-product controls
Lifecycle role	Existing franchise product	Differentiated subcutaneous lifecycle extension
Main technical risk	IV stability and infusion compatibility	Local tolerability, enzyme activity, viscosity, and subcutaneous dispersion

The formulation may allow Bristol Myers Squibb to retain patients and prescribers who prefer shorter administration. The commercial impact depends on reimbursement, site-of-care economics, patient preference, payer policies, and whether the subcutaneous product carries a price premium.

What is the FDA regulatory status of OPDIVO QVANTIG?

OPDIVO QVANTIG is FDA-approved, not an investigational product. Its label covers multiple adult cancer indications, with dosing determined by disease setting and combination therapy. [1]

Because the product combines a monoclonal antibody with hyaluronidase, future changes to the excipient system may require more than routine raw-material substitution. The regulatory impact depends on the nature of the change, the affected quality attributes, prior supplier qualification, analytical comparability, and the change-control history submitted to FDA.

A supplier change involving histidine or trehalose may be manageable with established comparability data. A change involving polysorbate 80 or hyaluronidase is more likely to receive heightened scrutiny because of potential effects on aggregation, particles, potency, local tolerability, and absorption.

How strong is the commercial opportunity for OPDIVO QVANTIG?

The opportunity is strongest in three areas.

First, qualified suppliers of polysorbate 80 and trehalose can benefit from recurring demand tied to a major oncology franchise. Second, recombinant hyaluronidase suppliers can pursue licensing and platform partnerships across multiple biologics. Third, CDMOs can offer integrated services covering antibody-enzyme co-formulation, sterile filling, analytical characterization, and stability studies.

Bristol Myers Squibb reported worldwide OPDIVO revenue of approximately $9 billion in 2024, making the franchise large enough to support meaningful lifecycle-management investment. The portion attributable to OPDIVO QVANTIG will depend on rollout speed, conversion from IV treatment, label expansion, payer adoption, and manufacturing capacity. [3]

The most defensible supplier position is a qualified, globally scalable excipient or enzyme platform with low change risk. Commodity pricing alone is less likely to displace an incumbent material after regulatory approval.

Key Takeaways

• OPDIVO QVANTIG combines nivolumab with hyaluronidase-nvhy for subcutaneous delivery.
• Its disclosed excipients are histidine, histidine hydrochloride monohydrate, methionine, polysorbate 80, trehalose dihydrate, and water for injection.
• Polysorbate 80 is the most visible recurring excipient opportunity, but its oxidation and degradation profile creates quality risk.
• Recombinant hyaluronidase is the highest-value technology component and offers licensing, supply, and platform-development opportunities.
• Excipient substitution is constrained by aggregation, particles, enzyme activity, injection-site tolerability, and regulatory comparability.
• The product gives Bristol Myers Squibb a subcutaneous lifecycle-management option for a multibillion-dollar nivolumab franchise.
• The strongest commercial positions will combine qualified supply, low impurity burden, regulatory documentation, and global manufacturing continuity.

FAQs

What is the main excipient in OPDIVO QVANTIG?

Hyaluronidase-nvhy is the key delivery-enabling component, while polysorbate 80, trehalose, histidine, and methionine support protein stability and product quality.

Does OPDIVO QVANTIG contain preservatives?

The FDA-labeled product is supplied as a preservative-free sterile injectable solution in a single-dose vial. [1]

Which excipient has the highest supply-chain risk?

Hyaluronidase-nvhy has the highest technical and qualification risk because it is a recombinant enzyme with activity, purity, and antibody-compatibility requirements. Polysorbate 80 has significant chemical and lot-variability risk.

Can a generic manufacturer replace the OPDIVO QVANTIG excipients?

A competing manufacturer would need to demonstrate that its formulation has comparable quality, stability, potency, safety, and delivery performance. Changes to hyaluronidase or polysorbate 80 would likely require substantial analytical and regulatory support.

What companies can benefit commercially from OPDIVO QVANTIG?

Potential beneficiaries include pharmaceutical-grade excipient suppliers, recombinant hyaluronidase developers, sterile injectable CDMOs, analytical testing providers, vial and stopper manufacturers, and companies offering subcutaneous biologic delivery platforms.

References

1. U.S. Food and Drug Administration. (2024). OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) injection, prescribing information. Bristol Myers Squibb.

2. Bookbinder, L. H., Hofer, A., Haller, M. F., et al. (2006). A recombinant human enzyme for enhanced interstitial transport of therapeutics. Journal of Controlled Release, 114(2), 230-241.

3. Bristol Myers Squibb. (2025). 2024 annual report. Bristol Myers Squibb.